NCT05324943 - A Gene Therapy Study in Patients With Gaucher Disease Type 1 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 15, 2022

Primary Completion Date

December 4, 2024

Study Completion Date

July 31, 2025

Conditions

Gaucher Disease, Type 1

Interventions

GENETIC

FLT201

FLT201 is a replication-incompetent single-stranded (ss) recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.

Trial Locations (10)

90027

Kaiser Permanente, Los Angeles

22030-6066

Lysosomal Rare Disorders Research and Treatment Center, Fairfax

Unknown

Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre

SphinCS, Höchheim

Shaare Zedek Medical Center, Jerusalem

Rabin Medical Center - PPDS, Petah Tikva

Tel Aviv Sourasky Medical Center, Tel Aviv

Hospital Quironsalud Zaragoza, Zaragoza

Royal Free Hospital, London

Salford Royal Hospital, Salford